TIDMISPH
RNS Number : 9699F
IS Pharma PLC
04 May 2011
FORM 8 (DD)
PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON
ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF
DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Identity of the party to the John Gregory
offer or person acting in concert
making the disclosure:
-------------------------------------- --------------------------------------
(b) Owner or controller of
interests and short positions
disclosed, if different from
1(a): The naming of nominee or
vehicle companies is
insufficient
-------------------------------------- --------------------------------------
(c) Name of offeror/offeree in IS Pharma plc
relation to whose relevant
securities this form relates: Use
a separate form for each
offeror/offeree
-------------------------------------- --------------------------------------
(d) Status of person making the Person acting in concert with the
disclosure: e.g. offeror, offeree
offeree, person acting in concert
with the offeror/offeree (specify
name of offeror/offeree)
-------------------------------------- --------------------------------------
(e) Date dealing undertaken: 4 May 2011
-------------------------------------- --------------------------------------
(f) Has the party previously NO
disclosed, or is it today If YES, specify which:
disclosing, under the Code in
respect of any other party to
this offer?
-------------------------------------- --------------------------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing
Class of relevant security: 10p Ordinary Shares
------------------------------------------ ----------------------------------
Interests Short positions
------------------------------------------ -------------- ------------------
Number % Number %
------------------------------------------ ------- ----- ----------- -----
(1) Relevant securities owned and/or
controlled: 93,701 0.18 Nil Nil
------------------------------------------ ------- ----- ----------- -----
(2) Derivatives (other than options): Nil Nil Nil Nil
------------------------------------------ ------- ----- ----------- -----
(3) Options and agreements to
purchase/sell: Nil Nil Nil Nil
------------------------------------------ ------- ----- ----------- -----
TOTAL: 93,701 0.18 Nil Nil
------------------------------------------ ------- ----- ----------- -----
All interests and all short positions should be disclosed.
Details of any open derivative or option positions, or
agreements to purchase or sell relevant securities, should be given
on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities (including directors'
and other executive options)
Class of relevant security in 10p Ordinary Shares
relation to which subscription right
exists:
-------------------------------------- --------------------------------------
Details, including nature of the 350,000 options exercisable at a
rights concerned and relevant price of 83.5p between 2 December
percentages: 2013 and 2 December 2020; and 49,207
options exercisable at a price of
70.0p between 30 July 2011 and 30
July 2018.
-------------------------------------- --------------------------------------
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE
(a) Purchases and sales
Class of relevant Purchase/sale Number of securities Price per unit
security
---------------------- -------------- --------------------- ---------------
N/A N/A N/A N/A
---------------------- -------------- --------------------- ---------------
(b) Derivatives transactions (other than options)
Class of Product Nature of dealing Number of Price per
relevant description e.g. reference unit
security e.g. CFD opening/closing a securities
long/short
position,
increasing/reducing
a long/short
position
------------ ------------- -------------------- ------------ -------------
N/A N/A N/A N/A N/A
------------ ------------- -------------------- ------------ -------------
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type e.g. Expiry Option
relevant description purchasing, securities price American, date money
security e.g. call selling, to which per European paid/
option varying option unit etc. received
etc. relates per
unit
--------- ------------ ------------ ----------- --------- ---------- ------- ---------
N/A N/A N/A N/A N/A N/A N/A N/A
--------- ------------ ------------ ----------- --------- ---------- ------- ---------
(ii) Exercising
Class of relevant Product Number of Exercise price
security description e.g. securities per unit
call option
------------------ ------------------ ------------------ ------------------
10p Ordinary Unapproved Share 44,386 70.0p
Shares Option Scheme -
Call Option
------------------ ------------------ ------------------ ------------------
(d) Other dealings (including subscribing for new
securities)
Class of relevant Nature of dealing Details Price per unit (if
security e.g. subscription, applicable)
conversion
---------------------- --------------------- -------- ---------------------
N/A N/A N/A N/A
---------------------- --------------------- -------- ---------------------
The currency of all prices and other monetary amounts should be
stated.
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or
any agreement or understanding, formal or informal,
relating to relevant securities which may be an inducement
to deal or refrain from dealing entered into by the
party to the offer or person acting in concert making
the disclosure and any other person:
If there are no such agreements, arrangements or understandings,
state "none"
------------------------------------------------------------------
None
------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to
options or derivatives
Details of any agreement, arrangement or understanding,
formal or informal, between the party to the offer
or person acting in concert making the disclosure
and any other person relating to:
(i) the voting rights of any relevant securities under
any option; or
(ii) the voting rights or future acquisition or disposal
of any relevant securities to which any derivative
is referenced:
If there are no such agreements, arrangements or understandings,
state "none"
----------------------------------------------------------------------
None
----------------------------------------------------------------------
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
------------------------------------- ---
Supplemental Form 8 (SBL) NO
------------------------------------- ---
Date of disclosure: 4 May 2011
--------------------- ----------------------------
Contact name: Matthew Hall, IS Pharma plc
--------------------- ----------------------------
Telephone number: 01244 625150
--------------------- ----------------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCAIMRTMBJMBMB
IS Pharma (LSE:ISPH)
過去 株価チャート
から 5 2024 まで 6 2024
IS Pharma (LSE:ISPH)
過去 株価チャート
から 6 2023 まで 6 2024
